|
| related topics |
| {product, candidate, development} |
| {product, market, service} |
| {product, liability, claim} |
| {acquisition, growth, future} |
| {property, intellectual, protect} |
| {personnel, key, retain} |
| {competitive, industry, competition} |
| {stock, price, operating} |
|
|
WE ARE DEPENDENT UPON OUR LICENSING AGREEMENTS WITH BD, AND IF BD IS NOT SUCCESSFUL IN SELLING, OR DETERMINES NOT TO PURSUE THE SALE OF, PRODUCTS INCORPORATING TECHNOLOGY LICENSED FROM US, OUR BUSINESS WILL BE HARMED.
IF WE ENGAGE IN ANY ACQUISITION OR BUSINESS COMBINATION, WE WILL INCUR A VARIETY OF RISKS THAT COULD ADVERSELY AFFECT OUR BUSINESS OPERATIONS.
IF WE ARE UNABLE TO RAISE ADDITIONAL FUNDS AS REQUIRED, WE MAY HAVE TO REDUCE THE SCOPE OF, OR CEASE, OUR OPERATIONS.
PRODUCTS INCORPORATING OUR TECHNOLOGY MUST RECEIVE REGULATORY APPROVAL IN THE UNITED STATES AND FOREIGN JURISDICTIONS; WE RELY ON OUR LICENSEES TO OBTAIN SUCH APPROVALS WHEN WE LICENSE OUR PRODUCT TECHNOLOGY, AND IF THEY ARE NOT SUCCESSFUL IN OBTAINING OR MAINTAINING APPROVALS, THE SALE OF PRODUCTS INCORPORATING OUR TECHNOLOGY AND OUR ABILITY TO REALIZE ROYALTY REVENUES WOULD BE IMPAIRED.
PRODUCTS MANUFACTURED UNDER OUR CONTROL THROUGH A CONTRACT MANUFACTURER MUST RECEIVE REGULATORY APPROVAL OR CLEARANCE AND IF WE ARE NOT SUCCESSFUL IN OBTAINING OR MAINTAINING SUCH APPROVALS OR CLEARANCES, WE WOULD NOT BE PERMITTED TO SELL THESE PRODUCTS.
WE ARE DEPENDENT ON OUR LICENSEES AND CONTRACT MANUFACTURERS FOR THE MANUFACTURE OF PRODUCTS INCORPORATING OUR TECHNOLOGY.
IF WE ARE UNABLE TO PROTECT OUR PROPRIETARY TECHNOLOGY, OR TO AVOID INFRINGING THE RIGHTS OF OTHERS, OUR ABILITY TO COMPETE EFFECTIVELY WILL BE IMPAIRED.
BECAUSE WE ARE DEPENDENT ON A SINGLE CORE TECHNOLOGY, WE ARE PARTICULARLY VULNERABLE TO THE DEVELOPMENT OF PRODUCTS INCORPORATING COMPETING TECHNOLOGY AND TECHNOLOGICAL CHANGE.
WE ARE DEPENDENT ON KEY PERSONNEL, AND IF WE ARE UNABLE TO RETAIN THESE PERSONNEL, OUR BUSINESS COULD BE HARMED.
PRODUCTS INCORPORATING OUR TECHNOLOGY MAY NOT ACHIEVE MARKET ACCEPTANCE.
WE ARE DEPENDENT ON THE SALES AND MARKETING EFFORTS OF OUR LICENSEES AND STRATEGIC COLLABORATORS TO SELL PRODUCTS INCORPORATING OUR TECHNOLOGY, AND OUR BUSINESS WILL SUFFER IF OUR LICENSEES OR STRATEGIC COLLABORATORS DO NOT SUCCESSFULLY MARKET THESE PRODUCTS.
WE ARE SUBJECT TO PRODUCT LIABILITY CLAIMS.
OUR MARKETS ARE HIGHLY COMPETITIVE.
OUR STOCK PRICE IS VOLATILE.
Full 10-K form ▸
|
|
| related documents |
| 816284--2/17/2009--CELGENE_CORP_/DE/ |
| 1063665--9/23/2010--CORGENIX_MEDICAL_CORP/CO |
| 926763--3/16/2006--ASV_INC_/MN/ |
| 38074--6/14/2006--FOREST_LABORATORIES_INC |
| 1062822--3/12/2007--LEXICON_GENETICS_INC/TX |
| 858803--12/18/2006--AVANIR_PHARMACEUTICALS |
| 810509--3/31/2008--NEOPROBE_CORP |
| 14272--2/22/2008--BRISTOL_MYERS_SQUIBB_CO |
| 64978--2/28/2008--MERCK_&_CO_INC |
| 926763--3/16/2007--ASV_INC_/MN/ |
| 908259--3/14/2007--OXIGENE_INC |
| 908259--3/14/2008--OXIGENE_INC |
| 1000694--3/6/2006--NOVAVAX_INC |
| 858803--12/17/2008--AVANIR_PHARMACEUTICALS |
| 708717--10/15/2007--ALFACELL_CORP |
| 897075--3/17/2008--REPROS_THERAPEUTICS_INC. |
| 23259--3/7/2007--CT_COMMUNICATIONS_INC_/NC |
| 858803--12/21/2007--AVANIR_PHARMACEUTICALS |
| 38074--5/30/2007--FOREST_LABORATORIES_INC |
| 38074--5/30/2008--FOREST_LABORATORIES_INC |
| 918112--11/6/2006--NEUROBIOLOGICAL_TECHNOLOGIES_INC_/CA/ |
| 849636--3/16/2006--CORTEX_PHARMACEUTICALS_INC/DE/ |
| 71478--3/15/2006--LIPID_SCIENCES_INC/ |
| 914475--2/7/2006--NEUROCRINE_BIOSCIENCES_INC |
| 310158--2/28/2007--SCHERING_PLOUGH_CORP |
| 64978--2/27/2009--MERCK_&_CO_INC |
| 14272--2/20/2009--BRISTOL_MYERS_SQUIBB_CO |
| 1096560--3/12/2008--SULPHCO_INC |
| 1038133--2/22/2010--HESKA_CORP |
| 1038133--3/3/2008--HESKA_CORP |
|